跳到正文
原文
Nature Medicine· Xiaoliang Zhao·· 16 天前AI 评分57

Ivonescimab与化疗或单药在可切除非小细胞肺癌中的II期试验

Perioperative ivonescimab with or without chemotherapy in resectable non-small cell lung cancer: a phase 2 trial

AI 导读

一项非随机II期试验中,可切除非小细胞肺癌患者接受Ivonescimab单药或联合化疗治疗,结果显示病理反应率令人鼓舞,持续的循环肿瘤DNA阴性可能预测治疗反应。

正文

Nature Medicine, Published online: 04 November 2026; doi:10.1038/s41591-026-04745-4

In a nonrandomized phase 2 trial, patients with resectable non-small cell lung cancer received perioperative ivonescimab as monotherapy or with chemotherapy, leading to encouraging pathological response rates in both cohorts, and sustained circulating tumor DNA negativity throughout neoadjuvant therapy may be predictive of response.

来源:Nature Medicine · nature.com